Cargando…
Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies
Complement dysregulation is characteristic of the renal diseases atypical hemolytic uremic syndrome (aHUS) and complement component 3 glomerulopathy (C3G). Complement regulatory protein Factor H (FH) inhibits complement activity, whereas FH-related proteins (FHRs) lack a complement regulatory domain...
Autores principales: | Loeven, Markus A., Maciej-Hulme, Marissa L., Yanginlar, Cansu, Hubers, Melanie C., Kellenbach, Edwin, de Graaf, Mark, van Kuppevelt, Toin H., Wetzels, Jack, Rabelink, Ton J., Smith, Richard J. H., van der Vlag, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416517/ https://www.ncbi.nlm.nih.gov/pubmed/34489931 http://dx.doi.org/10.3389/fimmu.2021.676662 |
Ejemplares similares
-
Blocking of inflammatory heparan sulfate domains by specific antibodies is not protective in experimental glomerulonephritis
por: van Gemst, Jasper J., et al.
Publicado: (2021) -
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
por: Buijsers, Baranca, et al.
Publicado: (2020) -
Differential binding of chemokines CXCL1, CXCL2 and CCL2 to mouse glomerular endothelial cells reveals specificity for distinct heparan sulfate domains
por: van Gemst, J. J., et al.
Publicado: (2018) -
ScFv Anti-Heparan Sulfate Antibodies Unexpectedly Activate Endothelial and Cancer Cells through p38 MAPK: Implications for Antibody-Based Targeting of Heparan Sulfate Proteoglycans in Cancer
por: Christianson, Helena C., et al.
Publicado: (2012) -
Molecular Interactions between Complement Factor H and Its Heparin and Heparan Sulfate Ligands
por: Perkins, Stephen J., et al.
Publicado: (2014)